AstraZeneca UK Ltd. has launched a patent infringement suit against Watson Pharmaceuticals Inc. in its most recent attempt to block generic-drug makers from producing copycat versions of its blockbuster cholesterol drug Crestor®. AstraZeneca's complaint, lodged Tuesday in the U.S. District Court for the District of Delaware, claims that Watson's new drug application for approval to market rosuvastatin zinc tablets infringes U.S. Patent Number RE37,314. Crestor®, a prescription drug belonging to a group of medicines that are used to treat high cholesterol, has been prescribed to more than 21 million patients worldwide and generated $4.5 billion in sales for AstraZeneca in 2009, according to the company. AstraZeneca is represented by Finnegan.
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Press Release
February 13, 2024
Commentary
Understanding IP Matters: The Mysteries of Design Patents – Preventing Abuse Before It Happens
February 7, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.